On Friday, Masimo Corporation (NASDAQ:MASI)’s shares inclined 5.80% to $38.84.
Masimo Corporation (MASI) declared that its Root® patient monitoring and connectivity platform has received the GOLD 2015 Medical Design Excellence Award — the highest award given in the general hospital devices and therapeutic products category. The 2015 Medical Design Excellence Award winners were honored recently at a presentation ceremony in New York City’s Jacob K. Javits Convention Center, in conjunction with the Medical Design & Manufacturing (MD&M) East Conference and Exposition (www.MDMEast.com).
Root comes with a dock for the Radical-7® handheld monitor or Radius-7® wearable monitor, an intuitive display, and multiple networking/connectivity options. Root integrates multiple streams of data on an easy-to-read, touch-screen.
Root innovations comprise:
- MOC-9™ - Flexible measurement expansion through Masimo Open Connect™ (MOC-9™) with MOC-9 modules from Masimo or third-party measurement by other companies to expand the platform’s measurements and capabilities. New MOC-9 modules in the U.S. will require new 510(k) clearances.
- ISA™ Capnography - CO2sidestream module featuring fast warm-up time and the innovative and cost-effective Nomoline™ sampling line.
- SedLine®brain function monitoring module, which provides four channels of EEG to assist clinicians better understand the effects of anesthesia on the brain.
- Iris™ connectivity gateway designed to provide integration for standalone devices such as IV pumps, ventilators, hospital beds, and other patient monitors. Iris enables Root to intake data from all devices connected to the patient, acting as an in-room patient monitor and connectivity hub. Alarms and alerts for all devices are seamlessly forwarded to the patient’s clinician and all device data are effortlessly documented in the patient’s electronic medical record.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. It offers Masimo Signal Extraction Technology (SET) with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
CYS Investments Inc (NYSE:CYS)’s shares dropped -0.58% to $8.64.
CYS Investments Inc (CYS) declared a quarterly dividend of $0.28 per share of common stock for the second quarter of 2015. The common stock dividend will be paid on July 15, 2015 to stockholders of record of common stock on June 22, 2015.
In accordance with the terms of the 7.75% Series A Cumulative Redeemable Preferred Stock (“Series A Preferred Stock”) of the Company, the Board of Directors of the Company has declared a Series A Preferred Stock cash dividend of $0.484375 per share of Series A Preferred Stock for the quarterly period that began on April 15, 2015, and ends on July 14, 2015. This dividend is payable on July 15, 2015 to stockholders of record of Series A Preferred Stock as of July 1, 2015.
CYS Investments, Inc., a specialty finance company, invests in residential mortgage pass-through securities in the United States. It also focuses on investing in residential mortgage-backed securities that are issued and the principal and interest of which are guaranteed by a federally chartered corporation (Agency RMBS); debt securities issued by the United States Department of Treasury or a government sponsored entity; and collateralized mortgage obligations issued by a government agency or government-sponsored entity that are collateralized by Agency RMBS.
At the end of Friday’s trade, Valeant Pharmaceuticals Intl Inc (NYSE:VRX)‘s shares dipped -1.81% to $229.64.
Valeant Pharmaceuticals Intl Inc (VRX) declared that it has sold 4.2 million shares of Valeant Pharmaceuticals International, Inc. in brokers’ transactions on the NYSE.
ValueAct Capital’s CEO Jeffrey W. Ubben said: “Mike Pearson and the Valeant team’s exceptional performance have once again caused their investment in Valeant to grow in value to well above 20% of our funds’ assets, and they are again compelled to reduce their position to rebalance their overall portfolio. They have owned Valeant shares for over nine years and have sold shares on three previous occasions for the same portfolio administration purposes. After this sale, their investment in Valeant will continue to be well in excess of $3.0bn and will be one of the largest investments in our funds.
Valeant Pharmaceuticals International, Inc. develops manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Qunar Cayman Islands Ltd (NASDAQ:QUNR), ended its Friday’s trading session with 0.04% gain, and closed at $48.69.
Hillhouse Capital Administration has filed an amended 13D from disclosing the enhance of the fund’s position in Qunar Cayman Islands Limited (NASDAQ:QUNR) to 20.24 million Class B ordinary shares. Precisely, the hedge fund run by Lei Zhang purchased 14.52 million additional shares in Qunar, with the total position now accounting for 12.99% of the company’s outstanding common stock. Moreover, Hillhouse Capital Administration revealed that the purpose of the transaction and its interest in the company is purely related to the predictable appreciation in the price of the purchased securities, which they have been very good at this year.
Professional investors like Lei Zhang spend considerable time and money conducting due diligence on each company they invest in, which makes them the perfect investors to emulate. However, we also know that the returns of hedge funds on the whole have not been good for several years, underperforming the market. We analyzed the historical stock picks of these investors and our research revealed that the small-cap picks of these funds performed far better than their large-cap picks, which is where most of their money is invested and why their performances as a whole have been poor. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic the best ideas of the best fund managers on your own? A portfolio compriseing of the 15 most popular small-cap stock picks among the funds we track has returned more than 142% and beaten the market by more than 84 percentage points since the end of August 2012, and by 4.6 percentage points in the first quarter of this year
Qunar Cayman Islands Limited operates an online travel commerce platform in the People’s Republic of China. The company through its platform provides a range of travel products comprising flight tickets, hotels, vacation packages, and attraction tickets, in addition to display advertising, train tickets, car services, smart lodging, and other services. Its customers comprise flight travel service providers, airlines, independent hotels, online travel agencies, insurance service providers, and others.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
